Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular

Detalhes bibliográficos
Autor(a) principal: Agren, Camila
Data de Publicação: 2017
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Biblioteca Digital de Teses e Dissertações da FAMERP
Texto Completo: http://bdtd.famerp.br/handle/tede/472
Resumo: Liver cancer ranks fifth in incidence and third in mortality worldwide. Most new cases and deaths occur in developing countries. Cirrhosis is a major risk factor for hepatocellular carcinoma (HCC). Several studies have shown that polymorphisms in cytochrome P450 (CYPs) genes can contribute to the etiology of complex diseases, as well as liver cancer. Polymorphisms in the genes of this family can alter the expression or function of the protein and influence the individual levels of detoxification, which contribute to the development of liver diseases. Objective: To investigate the association between the genetic polymorphisms CYP1A1*2A (rs4646903), CYP1A1*2C (rs1048943), CYP2E1*5B (rs2031920), CYP1E1*6 (rs6413432) and the risk of hepatic cirrhosis and HCC. Casuistic and Methods: Seven hundred and forty-five subjects (160 cirrhosis patients, 97 HCC patients and 488 controls) were evaluated. Polymorphisms were investigated by polymerase chain reaction / restriction fragment length polymorphism (PCR-RFLP) and Real-Time PCR. Statistical analyses were performed by chi-square and binary logistic regression. Survival analysis was performed using Kaplan Meier curve and Log rank test. Results: The results showed that age ≥ 60 years was associated with HCC (OR = 12.22, 95% CI: 7.17-20.82, p <0.001) and age ≥57 years was a risk factor for cirrhosis (OR = 7.12 CI 95% 4.68-10.84, p <0.001). Hepatitis B (OR = 7.84, 95% CI: 1.86-33.08, p = 0.005) and alpha fetoprotein> 500 ng / mL (OR = 3.73, 95% CI: 1.25-11, 13; p = 0.018) were associated with HCC. The polymorphisms CYP1A1 *2A, CYP1A1 *2C, CYP2E1 *5B and CYP2E1 *6 were not associated with risk of HCC and cirrhosis (p> 0.05), as well as CYP1A1 and CYP2E1 haplotypes (p > 0.05). There was no interaction between polymorphisms and smoking or alcohol consumption in the risk for HCC and cirrhosis (p> 0.05). No association was found between the polymorphisms and clinical parameters in HCC patients (p> 0.05). CYP2E1 *5B and CYP2E1 *6 polymorphisms were associated with a reduction in survival in HCC patients (p = 0.0234 and p = 0.0424, respectively). Conclusion: This study concludes that age is associated with the risk of developing HCC and cirrhosis, and CYP2E1 *5B and CYP2E1 *6 polymorphisms contribute for the reduced survival in HCC patients.
id FMRP_0e9974823ea353732eb7309502df07f4
oai_identifier_str oai:localhost:tede/472
network_acronym_str FMRP
network_name_str Biblioteca Digital de Teses e Dissertações da FAMERP
repository_id_str 4711
spelling Goloni-Bertollo, Eny Mariahttp://lattes.cnpq.br/9176636696202692Castanhole-Nunes, Márcia Maria Urbaninhttp://lattes.cnpq.br/0665944455231316Cintra, Mariangela Torreglosa Ruizhttp://lattes.cnpq.br/542081997039984835409856899http://lattes.cnpq.br/2023219167678846Agren, Camila2018-11-12T17:44:43Z2017-10-20Agren, Camila. Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular. 2017. 107 f. Dissertação (Programa de Pós-Graduação em Ciências da Saúde) - Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto.1334http://bdtd.famerp.br/handle/tede/472Liver cancer ranks fifth in incidence and third in mortality worldwide. Most new cases and deaths occur in developing countries. Cirrhosis is a major risk factor for hepatocellular carcinoma (HCC). Several studies have shown that polymorphisms in cytochrome P450 (CYPs) genes can contribute to the etiology of complex diseases, as well as liver cancer. Polymorphisms in the genes of this family can alter the expression or function of the protein and influence the individual levels of detoxification, which contribute to the development of liver diseases. Objective: To investigate the association between the genetic polymorphisms CYP1A1*2A (rs4646903), CYP1A1*2C (rs1048943), CYP2E1*5B (rs2031920), CYP1E1*6 (rs6413432) and the risk of hepatic cirrhosis and HCC. Casuistic and Methods: Seven hundred and forty-five subjects (160 cirrhosis patients, 97 HCC patients and 488 controls) were evaluated. Polymorphisms were investigated by polymerase chain reaction / restriction fragment length polymorphism (PCR-RFLP) and Real-Time PCR. Statistical analyses were performed by chi-square and binary logistic regression. Survival analysis was performed using Kaplan Meier curve and Log rank test. Results: The results showed that age ≥ 60 years was associated with HCC (OR = 12.22, 95% CI: 7.17-20.82, p <0.001) and age ≥57 years was a risk factor for cirrhosis (OR = 7.12 CI 95% 4.68-10.84, p <0.001). Hepatitis B (OR = 7.84, 95% CI: 1.86-33.08, p = 0.005) and alpha fetoprotein> 500 ng / mL (OR = 3.73, 95% CI: 1.25-11, 13; p = 0.018) were associated with HCC. The polymorphisms CYP1A1 *2A, CYP1A1 *2C, CYP2E1 *5B and CYP2E1 *6 were not associated with risk of HCC and cirrhosis (p> 0.05), as well as CYP1A1 and CYP2E1 haplotypes (p > 0.05). There was no interaction between polymorphisms and smoking or alcohol consumption in the risk for HCC and cirrhosis (p> 0.05). No association was found between the polymorphisms and clinical parameters in HCC patients (p> 0.05). CYP2E1 *5B and CYP2E1 *6 polymorphisms were associated with a reduction in survival in HCC patients (p = 0.0234 and p = 0.0424, respectively). Conclusion: This study concludes that age is associated with the risk of developing HCC and cirrhosis, and CYP2E1 *5B and CYP2E1 *6 polymorphisms contribute for the reduced survival in HCC patients.O câncer de fígado ocupa o quinto lugar em incidência e o terceiro em mortalidade em todo o mundo. A maioria dos novos casos e mortes ocorre em países em desenvolvimento. A cirrose é um dos principais fatores de risco para o desenvolvimento de carcinoma hepatocelular (CHC). Vários estudos demonstram que polimorfismos nos genes Citocromo P450 (CYPs) podem contribuir para a etiologia de doenças complexas, assim como o câncer de fígado. Os polimorfismos nos genes desta família podem alterar a expressão ou a função da proteína e influenciar os níveis individuais de detoxificação que contribuem para o desenvolvimento de doenças hepáticas. Objetivo: Investigar a associação dos polimorfismos CYP1A1*2A (rs4646903), CYP1A1*2C (rs1048943), CYP2E1*5B (rs2031920 e CYP1E1*6 (rs6413432) e o risco para cirrose e CHC. Casuística e métodos: Foram avaliados 745 indivíduos (160 pacientes com cirrose, 97 com CHC e 488 controles). Os polimorfismos foram investigados por Reação em Cadeia da Polimerase / Polimorfismo de Comprimento de Fragmento de Restrição (PCR-RFLP) e PCR em Tempo Real. As análises estatísticas foram realizadas por Qui-quadrado, Regressão logística binária. A análise de sobrevida foi realizada utilizando a Curva de Kaplan Meier e o teste Log-rank. Resultados: Os resultados mostraram que a idade ≥ 60 anos foi associada com CHC (OR = 12,22; IC 95%: 7,17-20,82; p <0,001) e idade ≥ 57 anos foi um fator de risco para cirrose (OR = 7,12 IC 95% 4,68-10,84; p < 001). Hepatite B (OR = 7,84; IC 95%: 1,86-33,08; p = 0,005) e alfa fetoproteína > 500 ng / mL (OR = 3,73; IC 95%: 1,25-11,13; p = 0,018) foram associadas com CHC. Os polimorfismos CYP1A1 *2A, CYP1A1 *2C, CYP2E1 *5B e CYP2E1 *6 não foram associados ao risco de CHC e cirrose (p> 0,05), assim como os haplótipos CYP1A1 e CYP2E1 (P> 0,05). Não houve interação entre os polimorfismos e o consumo de tabaco ou álcool no risco para CHC e cirrose (p> 0,05). Não foi observada associação entre os polimorfismos e parâmetros clínicos em pacientes com CHC (p> 0,05). Os polimorfismos CYP2E1 *5B e CYP2E1 *6 foram associados com redução da sobrevida em pacientes com CHC (p = 0,0234 e p = 0,0424, respectivamente). Conclusão: Este estudo conclui que a idade está associada ao risco de desenvolver CHC e cirrose e os polimorfismos CYP2E1 *5B e CYP2E1 *6 contribuem para a redução da sobrevida em pacientes com CHC.Submitted by Suzana Dias (suzana.dias@famerp.br) on 2018-11-12T17:44:43Z No. of bitstreams: 1 CamilaAgren_dissert.pdf: 1055624 bytes, checksum: b3b1d5227ab027ab3f0ff1f941091471 (MD5)Made available in DSpace on 2018-11-12T17:44:43Z (GMT). No. of bitstreams: 1 CamilaAgren_dissert.pdf: 1055624 bytes, checksum: b3b1d5227ab027ab3f0ff1f941091471 (MD5) Previous issue date: 2017-10-20Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES::2075167498588264571::600application/pdfporFaculdade de Medicina de São José do Rio PretoPrograma de Pós-Graduação em Ciências da Saúde::-6954410853678806574::500FAMERPBrasilFaculdade 1::Departamento 1::306626487509624506::500Polymorphism, GeneticLiver CirrhosisCarcinoma, HepatocellularPolimorfismo GenéticoCirrose HepáticaCarcinoma HepatocelularCIENCIAS DA SAUDE::8765449414823306929::600Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelularinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/openAccessreponame:Biblioteca Digital de Teses e Dissertações da FAMERPinstname:Faculdade de Medicina de São José do Rio Preto (FAMERP)instacron:FAMERPLICENSElicense.txtlicense.txttext/plain; charset=utf-82165bd3efa91386c1718a7f26a329fdcb468MD51ORIGINALCamilaAgren_dissert.pdfCamilaAgren_dissert.pdfapplication/pdf1055624b3b1d5227ab027ab3f0ff1f941091471MD52http://bdtd.famerp.br/bitstream/tede/472/1/license.txthttp://bdtd.famerp.br/bitstream/tede/472/2/CamilaAgren_dissert.pdftede/4722019-02-04 11:06:09.991oai:localhost: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Biblioteca Digital de Teses e Dissertaçõeshttp://bdtd.famerp.br/PUBhttps://bdtd.famerp.br/oai/requestsbdc@famerp.br||joao.junior@famerp.bropendoar:47112019-02-04T13:06:09Biblioteca Digital de Teses e Dissertações da FAMERP - Faculdade de Medicina de São José do Rio Preto (FAMERP)false
dc.title.por.fl_str_mv Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular
title Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular
spellingShingle Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular
Agren, Camila
Polymorphism, Genetic
Liver Cirrhosis
Carcinoma, Hepatocellular
Polimorfismo Genético
Cirrose Hepática
Carcinoma Hepatocelular
CIENCIAS DA SAUDE::8765449414823306929::600
title_short Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular
title_full Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular
title_fullStr Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular
title_full_unstemmed Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular
title_sort Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular
author Agren, Camila
author_facet Agren, Camila
author_role author
dc.contributor.advisor1.fl_str_mv Goloni-Bertollo, Eny Maria
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/9176636696202692
dc.contributor.referee1.fl_str_mv Castanhole-Nunes, Márcia Maria Urbanin
dc.contributor.referee1Lattes.fl_str_mv http://lattes.cnpq.br/0665944455231316
dc.contributor.referee2.fl_str_mv Cintra, Mariangela Torreglosa Ruiz
dc.contributor.referee2Lattes.fl_str_mv http://lattes.cnpq.br/5420819970399848
dc.contributor.authorID.fl_str_mv 35409856899
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/2023219167678846
dc.contributor.author.fl_str_mv Agren, Camila
contributor_str_mv Goloni-Bertollo, Eny Maria
Castanhole-Nunes, Márcia Maria Urbanin
Cintra, Mariangela Torreglosa Ruiz
dc.subject.eng.fl_str_mv Polymorphism, Genetic
Liver Cirrhosis
Carcinoma, Hepatocellular
topic Polymorphism, Genetic
Liver Cirrhosis
Carcinoma, Hepatocellular
Polimorfismo Genético
Cirrose Hepática
Carcinoma Hepatocelular
CIENCIAS DA SAUDE::8765449414823306929::600
dc.subject.por.fl_str_mv Polimorfismo Genético
Cirrose Hepática
Carcinoma Hepatocelular
dc.subject.cnpq.fl_str_mv CIENCIAS DA SAUDE::8765449414823306929::600
description Liver cancer ranks fifth in incidence and third in mortality worldwide. Most new cases and deaths occur in developing countries. Cirrhosis is a major risk factor for hepatocellular carcinoma (HCC). Several studies have shown that polymorphisms in cytochrome P450 (CYPs) genes can contribute to the etiology of complex diseases, as well as liver cancer. Polymorphisms in the genes of this family can alter the expression or function of the protein and influence the individual levels of detoxification, which contribute to the development of liver diseases. Objective: To investigate the association between the genetic polymorphisms CYP1A1*2A (rs4646903), CYP1A1*2C (rs1048943), CYP2E1*5B (rs2031920), CYP1E1*6 (rs6413432) and the risk of hepatic cirrhosis and HCC. Casuistic and Methods: Seven hundred and forty-five subjects (160 cirrhosis patients, 97 HCC patients and 488 controls) were evaluated. Polymorphisms were investigated by polymerase chain reaction / restriction fragment length polymorphism (PCR-RFLP) and Real-Time PCR. Statistical analyses were performed by chi-square and binary logistic regression. Survival analysis was performed using Kaplan Meier curve and Log rank test. Results: The results showed that age ≥ 60 years was associated with HCC (OR = 12.22, 95% CI: 7.17-20.82, p <0.001) and age ≥57 years was a risk factor for cirrhosis (OR = 7.12 CI 95% 4.68-10.84, p <0.001). Hepatitis B (OR = 7.84, 95% CI: 1.86-33.08, p = 0.005) and alpha fetoprotein> 500 ng / mL (OR = 3.73, 95% CI: 1.25-11, 13; p = 0.018) were associated with HCC. The polymorphisms CYP1A1 *2A, CYP1A1 *2C, CYP2E1 *5B and CYP2E1 *6 were not associated with risk of HCC and cirrhosis (p> 0.05), as well as CYP1A1 and CYP2E1 haplotypes (p > 0.05). There was no interaction between polymorphisms and smoking or alcohol consumption in the risk for HCC and cirrhosis (p> 0.05). No association was found between the polymorphisms and clinical parameters in HCC patients (p> 0.05). CYP2E1 *5B and CYP2E1 *6 polymorphisms were associated with a reduction in survival in HCC patients (p = 0.0234 and p = 0.0424, respectively). Conclusion: This study concludes that age is associated with the risk of developing HCC and cirrhosis, and CYP2E1 *5B and CYP2E1 *6 polymorphisms contribute for the reduced survival in HCC patients.
publishDate 2017
dc.date.issued.fl_str_mv 2017-10-20
dc.date.accessioned.fl_str_mv 2018-11-12T17:44:43Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv Agren, Camila. Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular. 2017. 107 f. Dissertação (Programa de Pós-Graduação em Ciências da Saúde) - Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto.
dc.identifier.uri.fl_str_mv http://bdtd.famerp.br/handle/tede/472
dc.identifier.doi.por.fl_str_mv 1334
identifier_str_mv Agren, Camila. Avaliação de polimorfismos dos genes CYP1A1 e CYP2E1 no risco para cirrose hepática e carcinoma hepatocelular. 2017. 107 f. Dissertação (Programa de Pós-Graduação em Ciências da Saúde) - Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto.
1334
url http://bdtd.famerp.br/handle/tede/472
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Faculdade de Medicina de São José do Rio Preto
dc.publisher.program.fl_str_mv Programa de Pós-Graduação em Ciências da Saúde::-6954410853678806574::500
dc.publisher.initials.fl_str_mv FAMERP
dc.publisher.country.fl_str_mv Brasil
dc.publisher.department.fl_str_mv Faculdade 1::Departamento 1::306626487509624506::500
publisher.none.fl_str_mv Faculdade de Medicina de São José do Rio Preto
dc.source.none.fl_str_mv reponame:Biblioteca Digital de Teses e Dissertações da FAMERP
instname:Faculdade de Medicina de São José do Rio Preto (FAMERP)
instacron:FAMERP
instname_str Faculdade de Medicina de São José do Rio Preto (FAMERP)
instacron_str FAMERP
institution FAMERP
reponame_str Biblioteca Digital de Teses e Dissertações da FAMERP
collection Biblioteca Digital de Teses e Dissertações da FAMERP
bitstream.url.fl_str_mv
http://bdtd.famerp.br/bitstream/tede/472/1/license.txt http://bdtd.famerp.br/bitstream/tede/472/2/CamilaAgren_dissert.pdf
bitstream.checksum.fl_str_mv bd3efa91386c1718a7f26a329fdcb468
b3b1d5227ab027ab3f0ff1f941091471
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Biblioteca Digital de Teses e Dissertações da FAMERP - Faculdade de Medicina de São José do Rio Preto (FAMERP)
repository.mail.fl_str_mv sbdc@famerp.br||joao.junior@famerp.br
_version_ 1809113653970993152